KOD
Kodiak Sciences Inc.
NasdaqGMUSDEQUITY
DELAYED
Last price
38.33
▼ 1.51 (3.79%)
MARKET · —
Price
Open
38.01
Prev close
39.84
Day high
40.90
Day low
37.99
Volume
498.84K
Market cap
—
P/E (TTM)
—
52W range
8.29 – 47.84
Trailing performance
Returnvs SPY
1W
-7.30%
-5.9%
1M
-6.56%
-10.3%
3M
+2.46%
-0.6%
6M
+51.62%
+40.6%
YTD
+37.09%
+24.8%
1Y
+303.47%
+283.5%
3Y
+1,379.92%
+1,305.8%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
41.01
-6.54% from price
SMA 20
41.68
-8.03% from price
SMA 50
39.76
-3.61% from price
SMA 100
39.75
-3.58% from price
SMA 200
32.19
+19.08% from price
EMA 12
40.83
-6.13% from price
EMA 26
40.98
-6.47% from price
EMA 50
40.11
-4.44% from price
RSI (14)
41.5
Neutral
MACD (12,26,9)
-0.15
Hist -0.60
ATR (14)
2.91
7.58% of price
Realised vol 30D
56.0%
Annualised
Bollinger upper
45.40
20, 2σ
Bollinger lower
37.95
20, 2σ
50 / 200 cross
Golden
39.76 vs 32.19
Trend bias
Above 200
+19.08%
Risk profile
Beta vs SPY
1.16
More volatile than market
Correlation to SPY
0.12
Largely independent
Realised vol 30D
56.0%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-36.2%
Peak to trough
Max drawdown 5Y
-98.9%
Peak to trough
ATR 14
2.91
7.58% of price
Beta (reported)
—
5Y monthly, from filing
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Kodiak's Q2 Loss Wider Than Expected, Pipeline Development in Focus
Zacks · 8d ago
Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2026 Financial Results
PR Newswire · 9d ago
KOD Begins Late-Stage Study of KSI-501 in Diabetic Macular Edema
Zacks · 11d ago
Kodiak Sciences Says First Patients Enrolled in Late-Stage Diabetic Eye Disease Trial
MT Newswires · 12d ago
Kodiak Sciences Announces First Patients Enrolled in Global Phase 3 ALTO trial of KSI-501 in Patients with Diabetic Macular Edema
PR Newswire · 12d ago
Kodiak Sciences Completes Enrollment in First Pivotal Cohort in the Phase 3 PEAK Trial of KSI-101 for Macular Edema Secondary to Inflammation and Reaffirms Topline Clinical Data Release Remains on Track for December 2026
PR Newswire · 16d ago
Kodiak CFO Sells $1 Million in Stock as Shares Surge 650%. What Investors Should Know
Motley Fool · 74d ago
Kodiak Sciences (KOD) Is Down 15.4% After Strong Zenkuda GLOW2 Data And Accelerated Filing Plans
Simply Wall St. · 77d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.